Famvir (Famciclovir)
Antiviral medication for shingles, genital herpes and cold sores
Quick Facts about Famvir
Key Takeaways about Famvir
- Prodrug advantage: Famciclovir is rapidly converted to penciclovir in the body, achieving approximately 77% oral bioavailability – significantly higher than acyclovir
- Start early for best results: Treatment of shingles should begin within 72 hours of rash onset; for recurrent herpes, start at the first sign of tingling or prodromal symptoms
- Convenient dosing: Cold sores can be treated with a single-day regimen (1500 mg single dose or 750 mg twice daily), and shingles requires only three-times-daily dosing
- Dose adjustment for kidneys: Patients with impaired renal function (creatinine clearance below 60 mL/min) require dose reduction to prevent drug accumulation
- Does not eliminate latent virus: Like all antiherpes drugs, famciclovir suppresses active viral replication but does not eradicate the latent virus from nerve ganglia
What Is Famvir and What Is It Used For?
Famvir (famciclovir) is a prescription antiviral medication used to treat herpes zoster (shingles), recurrent genital herpes, and recurrent cold sores. It is a prodrug that is converted to the active antiviral compound penciclovir in the body, which inhibits herpes virus DNA replication.
Famciclovir belongs to the class of nucleoside analogue antiviral agents. After oral administration, famciclovir undergoes rapid and extensive first-pass metabolism to form penciclovir, its pharmacologically active metabolite. Penciclovir is selectively activated by viral thymidine kinase in cells infected with herpes simplex virus (HSV) or varicella-zoster virus (VZV), making it a highly targeted antiviral agent with minimal effect on uninfected host cells.
The medication is effective against several herpes virus species, including herpes simplex virus type 1 (HSV-1, which typically causes cold sores), herpes simplex virus type 2 (HSV-2, the primary cause of genital herpes), and varicella-zoster virus (VZV, the cause of chickenpox and shingles). While famciclovir also demonstrates in vitro activity against Epstein-Barr virus (EBV), hepatitis B virus (HBV), and cytomegalovirus (CMV), its primary clinical indications are limited to HSV and VZV infections.
Famciclovir was first approved by the U.S. Food and Drug Administration (FDA) in 1994 for the treatment of herpes zoster. Since then, its indications have expanded to include the treatment and suppression of recurrent genital herpes and the treatment of recurrent herpes labialis (cold sores). It is marketed under the brand name Famvir, manufactured originally by Novartis and now available from various generic manufacturers worldwide.
Approved Indications
Famvir is approved for the following clinical uses in immunocompetent adults:
- Herpes zoster (shingles): Treatment of acute herpes zoster to reduce the duration of viral shedding, accelerate healing of skin lesions, and reduce the severity and duration of post-herpetic neuralgia (PHN), the chronic nerve pain that can follow shingles
- Recurrent genital herpes – episodic treatment: Treatment of recurrent episodes of genital herpes to reduce outbreak duration, accelerate lesion healing, and decrease viral shedding
- Recurrent genital herpes – suppressive therapy: Long-term daily suppressive treatment to reduce the frequency of recurrent genital herpes outbreaks and lower the risk of transmission to sexual partners
- Recurrent herpes labialis (cold sores): Single-day treatment of recurrent cold sores in immunocompetent adults, initiated at the earliest sign of a developing lesion
How Famciclovir Works
The antiviral mechanism of famciclovir involves a multi-step activation process. After oral ingestion, famciclovir is rapidly absorbed from the gastrointestinal tract and converted to penciclovir through deacetylation and oxidation during first-pass metabolism. Once penciclovir enters virus-infected cells, it is phosphorylated by viral thymidine kinase to penciclovir monophosphate, which is then further phosphorylated by cellular kinases to penciclovir triphosphate – the active antiviral compound.
Penciclovir triphosphate competitively inhibits viral DNA polymerase and, when incorporated into the growing DNA chain, impairs further elongation. This effectively halts viral DNA replication and prevents the production of new virus particles. A key pharmacological advantage of penciclovir triphosphate is its prolonged intracellular half-life of 7 to 20 hours in herpes-infected cells, compared to approximately 0.7 to 1 hour for acyclovir triphosphate. This sustained intracellular activity contributes to the efficacy of famciclovir even with less frequent dosing.
While both drugs target the same viral enzyme (DNA polymerase), famciclovir offers several pharmacokinetic advantages. The oral bioavailability of penciclovir from famciclovir is approximately 77%, compared to only 10–20% for acyclovir. Additionally, penciclovir triphosphate remains active inside infected cells for much longer (7–20 hours vs 0.7–1 hour). In clinical trials, both drugs demonstrate comparable efficacy for most herpes infections, but famciclovir may offer greater convenience due to its dosing schedule.
What Should You Know Before Taking Famvir?
Before taking Famvir, inform your doctor about any kidney problems, immune system disorders, lactose intolerance, or if you are pregnant or breastfeeding. Famvir requires dose adjustment in patients with reduced kidney function and is not recommended for children under 18 years.
Before starting treatment with Famvir, it is essential that your healthcare provider has a complete understanding of your medical history, current medications, and any known allergies. This information helps ensure that famciclovir is safe and appropriate for your specific situation. Like all prescription medications, Famvir carries certain risks and contraindications that must be considered before initiating therapy.
Contraindications
Famvir is contraindicated in patients with a known hypersensitivity to famciclovir, penciclovir, or any of the excipients contained in the formulation. Patients who have experienced allergic reactions to penciclovir cream (a topical formulation of the active metabolite) should also avoid famciclovir, as cross-sensitivity may occur. Signs of hypersensitivity may include rash, urticaria, angioedema, or anaphylaxis.
Famvir tablets contain lactose. Patients with rare hereditary problems of galactose intolerance, total lactase deficiency, or glucose-galactose malabsorption should not take this medicine. The lactose content should be taken into consideration for patients with diabetes mellitus, although the amount is generally clinically insignificant.
Warnings and Precautions
Several important precautions should be observed when using famciclovir:
- Renal impairment: Penciclovir is primarily eliminated by the kidneys. Patients with impaired renal function (creatinine clearance below 60 mL/min) require dose adjustment to prevent drug accumulation and potential toxicity. Elderly patients should have their kidney function assessed before starting treatment, as age-related decline in renal function is common
- Immunocompromised patients: The efficacy and safety of famciclovir have not been well established in severely immunocompromised patients (such as those with advanced HIV, bone marrow transplant recipients, or those undergoing chemotherapy). In these populations, antiviral resistance may emerge, and alternative therapies such as intravenous acyclovir or foscarnet may be more appropriate
- Hepatic impairment: Although famciclovir undergoes hepatic metabolism, studies in patients with mild to moderate liver disease have shown no clinically significant changes in penciclovir pharmacokinetics. However, the conversion of famciclovir to penciclovir may be impaired in severe hepatic insufficiency, and caution is advised
- Paediatric use: Famvir is not recommended for use in children and adolescents under 18 years of age due to insufficient data on safety and efficacy in this population
- Galactose intolerance: Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency, or glucose-galactose malabsorption should not take famciclovir tablets
Pregnancy and Breastfeeding
The safety of famciclovir during pregnancy has not been established through adequate controlled clinical studies in humans. Animal reproduction studies (in rats and rabbits at doses substantially higher than therapeutic doses) have not revealed evidence of teratogenicity or impaired fertility. However, as animal studies are not always predictive of human response, famciclovir should only be used during pregnancy when the potential benefit clearly justifies the potential risk to the fetus.
It is not known whether famciclovir or penciclovir is excreted in human breast milk. In animal studies, penciclovir was detected in the breast milk of lactating rats following oral administration of famciclovir. Given the potential for adverse reactions in nursing infants, a decision should be made whether to discontinue breastfeeding or to discontinue the drug, taking into account the importance of the medication to the mother. Women of childbearing potential should use effective contraception during treatment and discuss family planning with their healthcare provider.
Kidney disease or reduced kidney function, a weakened immune system (including HIV/AIDS), liver disease, galactose intolerance or lactase deficiency, or if you are pregnant, planning to become pregnant, or breastfeeding. These conditions may require dose adjustment, additional monitoring, or selection of an alternative therapy.
How Does Famvir Interact with Other Drugs?
Famciclovir has relatively few clinically significant drug interactions. The most notable interaction is with probenecid, which can increase penciclovir blood levels by reducing its renal clearance. Concurrent use with other nephrotoxic drugs should be approached with caution.
Drug interactions with famciclovir are generally limited because penciclovir, its active metabolite, is primarily eliminated by the kidneys through a combination of glomerular filtration and active tubular secretion. Famciclovir is not significantly metabolised by the cytochrome P450 enzyme system, which reduces the risk of interactions with drugs that are substrates, inhibitors, or inducers of CYP enzymes. Nonetheless, certain interactions warrant clinical attention.
In vitro studies have demonstrated that penciclovir does not inhibit or induce the major CYP450 isoenzymes (CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP3A4) at clinically relevant concentrations. This is an important advantage for patients who take multiple medications, as the risk of pharmacokinetic interactions is low. However, pharmacodynamic interactions and interactions affecting renal elimination remain possible.
| Drug | Interaction Type | Clinical Effect | Recommendation |
|---|---|---|---|
| Probenecid | Pharmacokinetic | Increases penciclovir plasma levels by inhibiting renal tubular secretion | Monitor for increased side effects; dose adjustment may be needed |
| Raloxifene | Pharmacokinetic | May increase penciclovir levels through inhibition of renal clearance | Use with caution; monitor renal function |
| Zidovudine (AZT) | Pharmacokinetic | No clinically significant interaction demonstrated in studies, but both are renally cleared | No dose adjustment required; standard monitoring |
| Digoxin | Pharmacokinetic | No significant interaction observed in clinical studies | No dose adjustment required |
| Cimetidine | Pharmacokinetic | May slightly increase penciclovir levels by inhibiting aldehyde oxidase metabolism | Clinically insignificant; no adjustment needed |
| Theophylline | Pharmacokinetic | No clinically significant interaction observed | No dose adjustment required |
| Emtricitabine | Pharmacodynamic | Both are nucleoside analogues; potential for additive antiviral effects but also additive toxicity | Use with caution; monitor for adverse effects |
Major Interactions
The most clinically significant drug interaction involving famciclovir is with probenecid, a uricosuric agent used to treat gout. Probenecid inhibits the renal tubular secretion of penciclovir, which can lead to a significant increase in penciclovir plasma concentrations (up to 40% increase in AUC). Patients taking both medications concurrently should be monitored for signs of penciclovir-related side effects, and dose reduction of famciclovir may be warranted, particularly in patients with pre-existing renal impairment.
Concurrent administration of famciclovir with other drugs that are cleared by active renal tubular secretion – such as tenofovir, cidofovir, or aminoglycosides – could theoretically result in competition for renal elimination and elevated levels of either drug. While no formal interaction studies have been conducted for all such combinations, clinicians should be vigilant for signs of toxicity and consider monitoring renal function more frequently when these drugs are co-prescribed.
Minor Interactions
Clinical pharmacokinetic studies have shown no significant interactions between famciclovir and a range of commonly prescribed medications, including allopurinol, digoxin, cimetidine, theophylline, and magnesium/aluminium hydroxide antacids. Co-administration of famciclovir with food delays the absorption of famciclovir (increases time to maximum plasma concentration by approximately 1.5 hours) but does not significantly affect the overall extent of absorption (AUC). Therefore, famciclovir can be taken with or without food.
Although famciclovir is not known to interact with alcohol through pharmacokinetic mechanisms, both substances can individually cause headache, nausea, and dizziness. Patients should be advised to limit alcohol consumption during treatment to reduce the risk of additive side effects.
What Is the Correct Dosage of Famvir?
Famvir dosage varies by indication: 500 mg three times daily for 7 days for shingles, 125 mg twice daily for 5 days for recurrent genital herpes episodes, 250 mg twice daily for suppressive genital herpes therapy, and 1500 mg as a single dose for cold sores. All doses require adjustment in patients with renal impairment.
The correct dosage of Famvir depends on the specific indication being treated, the patient’s kidney function, and whether the treatment is episodic or suppressive. Famciclovir is available as film-coated tablets for oral administration. The tablets should be swallowed whole with water and can be taken with or without food, as food does not significantly affect overall drug absorption.
For all indications, treatment should be initiated as early as possible after the onset of signs or symptoms. In herpes zoster, treatment within 72 hours of rash onset is associated with the best clinical outcomes, including reduced duration of viral shedding, faster healing, and decreased risk of post-herpetic neuralgia. For recurrent genital herpes and cold sores, treatment should ideally begin during the prodromal phase (tingling, burning, or itching sensation) before lesions appear.
| Indication | Dose | Frequency | Duration |
|---|---|---|---|
| Herpes zoster (shingles) | 500 mg | Three times daily | 7 days |
| Genital herpes – first episode | 250 mg | Three times daily | 5 days |
| Genital herpes – recurrent episode | 125 mg | Twice daily | 5 days |
| Genital herpes – suppressive therapy | 250 mg | Twice daily | Up to 12 months (reassess) |
| Cold sores (herpes labialis) | 1500 mg | Single dose | 1 day |
Adults
For herpes zoster (shingles), the recommended dose is 500 mg three times daily for 7 days. Treatment should commence as soon as possible after diagnosis, ideally within 72 hours of onset of the rash. Clinical studies have demonstrated that famciclovir 500 mg three times daily is as effective as acyclovir 800 mg five times daily in accelerating cutaneous healing and reducing the duration and severity of zoster-associated pain, while offering the advantage of a simpler dosing regimen.
For recurrent genital herpes, episodic treatment consists of 125 mg twice daily for 5 days. Patient-initiated therapy, where the patient begins treatment at the first sign of a recurrence, is the most effective approach. In clinical studies, famciclovir significantly reduced the median time to healing of lesions and the duration of viral shedding compared to placebo. For suppressive therapy, the dose is 250 mg twice daily for up to 12 months, after which the need for continued treatment should be reassessed. Long-term suppressive therapy with famciclovir has been shown to reduce recurrence rates by approximately 70–80%.
For recurrent herpes labialis (cold sores), a single-day treatment regimen is approved: 1500 mg as a single dose or 750 mg twice daily for one day. This convenient regimen has been shown to reduce the time to healing by approximately 2 days compared to placebo, provided treatment is started at the first sign of a recurrence.
Dose Adjustment in Renal Impairment
Since penciclovir is primarily eliminated by renal excretion, dose adjustments are essential in patients with reduced kidney function. The following modifications are recommended based on creatinine clearance (CrCl):
| Creatinine Clearance | Dose | Frequency |
|---|---|---|
| ≥ 60 mL/min | 500 mg | Three times daily |
| 40–59 mL/min | 500 mg | Twice daily |
| 20–39 mL/min | 500 mg | Once daily |
| < 20 mL/min | 250 mg | Once daily |
| Haemodialysis | 250 mg | After each dialysis session |
Children
Famvir is not recommended for use in children and adolescents under 18 years of age. The safety and efficacy of famciclovir in the paediatric population have not been established through adequate clinical studies. For herpes virus infections in children, acyclovir and valacyclovir are the preferred antiviral agents, as they have been more extensively studied in paediatric patients and have established dosing guidelines for various age groups.
Elderly
No dose adjustment is required solely on the basis of age. However, elderly patients are more likely to have reduced renal function, and the dose should be adjusted according to the patient’s creatinine clearance as described above. Healthcare providers should assess renal function before initiating treatment in elderly patients and periodically thereafter, particularly during prolonged courses of therapy. Elderly patients should also be monitored for neurological side effects such as confusion or disorientation.
Missed Dose
If you miss a dose of Famvir, take it as soon as you remember. However, if it is almost time for your next scheduled dose, skip the missed dose and continue with your regular dosing schedule. Do not take a double dose to make up for a missed one. For conditions where famciclovir is taken for a short duration (such as the 5-day course for recurrent genital herpes or the 7-day course for shingles), it is important to complete the full course of treatment even if symptoms begin to improve before the course is finished.
Overdose
In cases of overdose with famciclovir, symptomatic and supportive care should be provided. There is no specific antidote for famciclovir overdose. Since penciclovir is eliminated by the kidneys, haemodialysis may be considered in severe cases, as it can enhance the removal of penciclovir from the body. In clinical studies, single doses up to 1500 mg and multiple doses up to 750 mg three times daily for prolonged periods have been administered without serious adverse events beyond those described in the side effects section. In the event of overdose, patients should be monitored for signs of toxicity, particularly renal impairment and neurological symptoms.
What Are the Side Effects of Famvir?
The most common side effects of Famvir are headache, nausea, and dizziness, which occur at rates similar to placebo in clinical trials. Serious side effects including severe allergic reactions, confusion, and hallucinations are rare and more likely in elderly patients or those with kidney impairment.
Famciclovir is generally well tolerated, with a side effect profile comparable to placebo in large randomised controlled clinical trials. The most frequently reported adverse events during clinical studies were headache, nausea, and dizziness. These effects are usually mild to moderate in severity and resolve without the need to discontinue treatment. The risk of side effects may be increased in patients with impaired renal function due to reduced drug clearance, and in elderly patients.
The following side effects have been reported during clinical trials and post-marketing surveillance. They are organised by frequency according to the internationally standardised classification system used in regulatory medicine. It is important to note that causality cannot always be established from spontaneous reports, and some listed effects may not be directly caused by the medication.
Signs of a severe allergic reaction (anaphylaxis or angioedema), which may include sudden swelling of the face, lips, tongue, or throat, difficulty breathing, severe skin rash with blistering, or collapse. Although extremely rare, these reactions require emergency treatment. Also seek urgent care if you experience confusion, hallucinations, or altered consciousness.
Common Side Effects
- Headache
- Nausea
- Dizziness
Uncommon Side Effects
- Diarrhoea
- Vomiting
- Abdominal pain
- Flatulence
- Skin rash (including pruritus and urticaria)
- Fatigue
- Somnolence (drowsiness)
Rare Side Effects
- Confusion and disorientation
- Hallucinations (primarily in elderly patients)
- Jaundice and abnormal liver function tests
- Cholestatic hepatitis
- Thrombocytopenia (reduced platelet count)
Very Rare Side Effects
- Severe allergic reactions (anaphylaxis, angioedema)
- Erythema multiforme
- Stevens-Johnson syndrome
- Toxic epidermal necrolysis
- Palpitations
Neurological Side Effects
Neurological adverse effects of famciclovir merit particular attention. While headache and dizziness are common and generally benign, more serious neurological events – including confusion, hallucinations, and disorientation – have been reported, predominantly in elderly patients and those with impaired renal function. These effects are thought to be related to accumulation of penciclovir or its metabolites when renal clearance is reduced. They are generally reversible upon dose reduction or discontinuation of the drug. Patients experiencing any neurological symptoms should report them to their healthcare provider promptly.
Hepatic Effects
Rare cases of liver-related adverse events have been reported with famciclovir, including elevated liver enzymes (transaminases and bilirubin), jaundice, and cholestatic hepatitis. These events have primarily occurred in patients with underlying liver disease or those taking other hepatotoxic medications. Liver function tests should be considered in patients who develop symptoms suggestive of hepatic dysfunction, such as unexplained nausea, vomiting, abdominal pain, or jaundice during treatment.
Reporting Side Effects
If you experience any side effects, including those not listed here, talk to your doctor or pharmacist. You can also report side effects to your national medicines regulatory authority (for example, the FDA MedWatch programme in the United States, the Yellow Card Scheme in the United Kingdom, or the EMA EudraVigilance system in Europe). Reporting helps improve knowledge about the safety of medications and may contribute to the identification of previously unrecognised adverse reactions.
How Should You Store Famvir?
Store Famvir tablets below 30°C (86°F) in a dry place. Keep the tablets in their original packaging to protect from moisture. Keep out of sight and reach of children. Do not use after the expiry date on the packaging.
Proper storage of medications is essential to maintain their effectiveness, stability, and safety throughout their shelf life. Famvir film-coated tablets should be stored at room temperature, not exceeding 30°C (86°F). Avoid exposing the tablets to excessive heat, humidity, or direct sunlight, as these environmental conditions can degrade the active ingredient and reduce the medication’s efficacy.
Keep the tablets in their original blister packaging until it is time to take them. The blister pack provides protection against moisture and light. If the tablets are dispensed in a bottle, ensure the cap is tightly closed after each use. Do not store Famvir in bathrooms or other areas where moisture levels are high, as humidity can compromise tablet integrity.
Always keep Famvir and all medicines out of the sight and reach of children. Accidental ingestion by children can cause serious harm. Do not use Famvir after the expiry date stated on the carton, blister pack, or bottle label. The expiry date refers to the last day of that month.
Do not dispose of medications via wastewater or household waste. Return any unused or expired medicines to your pharmacy for safe and environmentally responsible disposal. Many countries have take-back programmes or designated disposal facilities for pharmaceutical waste. Proper disposal prevents environmental contamination and reduces the risk of accidental exposure.
What Does Famvir Contain?
Each Famvir 125 mg film-coated tablet contains 125 mg of famciclovir as the active ingredient. Inactive ingredients include hydroxypropyl cellulose, lactose, magnesium stearate, sodium starch glycolate, and a film coating based on hypromellose, polyethylene glycol, and titanium dioxide.
Understanding the composition of your medication is important, particularly if you have known allergies or intolerances to specific substances. Below is a detailed breakdown of the active and inactive ingredients in Famvir tablets.
Active Ingredient
The active substance is famciclovir. Each film-coated tablet contains 125 mg of famciclovir. Famciclovir is a white to off-white powder with the chemical name 2-[2-(2-amino-9H-purin-9-yl)ethyl]-1,3-propanediol diacetate. Its molecular formula is C14H19N5O4 and it has a molecular weight of 321.34 g/mol. Famciclovir itself is pharmacologically inactive and serves as a prodrug that is rapidly and extensively converted to the active antiviral agent penciclovir after oral administration.
Inactive Ingredients (Excipients)
Tablet core:
- Hydroxypropyl cellulose: A cellulose-based polymer used as a binder to hold the tablet together
- Lactose: A sugar derived from milk, used as a filler to give the tablet appropriate size and weight
- Magnesium stearate: A lubricant used in tablet manufacturing to prevent ingredients from sticking to equipment
- Sodium starch glycolate: A disintegrant that helps the tablet break apart in the gastrointestinal tract for proper absorption
Film coating:
- Hypromellose (hydroxypropyl methylcellulose): Forms the basis of the film coating that protects the tablet and aids swallowing
- Polyethylene glycol (macrogol): A plasticiser used in the film coating to improve flexibility and appearance
- Titanium dioxide (E171): A white pigment used to colour the film coating and provide opacity
Famvir tablets contain lactose as an excipient. Patients with rare hereditary problems of galactose intolerance, total lactase deficiency, or glucose-galactose malabsorption should not take these tablets. The amount of lactose per tablet is small and unlikely to cause symptoms in most patients with mild lactose intolerance.
Frequently Asked Questions about Famvir
Famvir (famciclovir) is an antiviral medication prescribed for the treatment of herpes zoster (shingles), treatment and suppression of recurrent genital herpes, and single-day treatment of recurrent cold sores (herpes labialis) in immunocompetent adults. It works by being converted to penciclovir in the body, which inhibits herpes virus DNA replication and reduces viral shedding, symptom severity, and healing time.
Famvir is rapidly absorbed and converted to its active form penciclovir within hours of the first dose. Symptom improvement typically becomes noticeable within 2 to 3 days. For shingles, treatment should begin within 72 hours of rash onset for best results. For cold sores, the single-day treatment (1500 mg) can reduce healing time by about 2 days compared to no treatment, provided it is started at the first sign of tingling or itching.
Both Famvir and acyclovir target herpes viruses, but they differ in pharmacokinetics. Famciclovir achieves approximately 77% oral bioavailability (compared to about 20% for acyclovir), and its active metabolite penciclovir triphosphate has a much longer intracellular half-life (7–20 hours versus less than 1 hour for acyclovir triphosphate). This allows for less frequent dosing with Famvir. Clinical efficacy is comparable for most herpes infections. Famvir also offers a unique single-day treatment option for cold sores.
No, Famvir does not cure herpes. Herpes viruses establish lifelong latent infections in nerve ganglia (nerve cell clusters). Famvir works by inhibiting active viral replication during outbreaks, which reduces the severity and duration of symptoms and decreases the amount of virus shed. When taken as daily suppressive therapy, it can significantly reduce the frequency of recurrent outbreaks and lower the risk of transmission to others, but the underlying latent infection persists.
Famvir should only be used during pregnancy when the potential benefit justifies the potential risk to the fetus. There are no adequate controlled studies in pregnant women. Animal studies have not shown harmful effects at therapeutic doses. If you are pregnant, planning to become pregnant, or breastfeeding, discuss the risks and benefits with your healthcare provider. Your doctor may consider using acyclovir or valacyclovir instead, as these drugs have more established safety data in pregnancy.
No, Famvir can be taken with or without food. While food may slightly delay the absorption of famciclovir (increasing the time to reach peak blood levels), it does not significantly affect the total amount of drug absorbed. Therefore, food intake does not impact the overall efficacy of the treatment, and you can take Famvir at whichever time is most convenient for you.
References
All information in this article is based on peer-reviewed medical literature, international clinical guidelines, and official regulatory documents. The following sources were consulted:
- European Medicines Agency (EMA). Famvir Summary of Product Characteristics (SmPC). Last updated 2024. Available at: ema.europa.eu
- U.S. Food and Drug Administration (FDA). Famvir (famciclovir) Prescribing Information. Reference ID: 4908421. Available at: accessdata.fda.gov
- British National Formulary (BNF). Famciclovir monograph. Last reviewed January 2026. Available at: bnf.nice.org.uk
- Pue MA, Benet LZ. Pharmacokinetics of famciclovir in man. Antiviral Chemistry & Chemotherapy. 1993;4(Suppl 1):47–55. doi:10.1177/09563202930040S106
- Tyring S, Barbarash RA, Nahlik JE, et al. Famciclovir for the treatment of acute herpes zoster: effects on acute disease and postherpetic neuralgia. Annals of Internal Medicine. 1995;123(2):89–96. doi:10.7326/0003-4819-123-2-199507150-00002
- Sacks SL, Aoki FY, Diaz-Mitoma F, et al. Patient-initiated, twice-daily oral famciclovir for early recurrent genital herpes. JAMA. 1996;276(1):44–49. doi:10.1001/jama.276.1.44
- Spruance SL, Tyring SK, DeGregorio B, et al. A large-scale, placebo-controlled, dose-ranging trial of peroral valaciclovir for episodic treatment of recurrent herpes genitalis. Archives of Internal Medicine. 1996;156(15):1729–1735.
- Diaz-Mitoma F, Sibbald RG, Shafran SD, et al. Oral famciclovir for the suppression of recurrent genital herpes: a randomized controlled trial. JAMA. 1998;280(10):887–892. doi:10.1001/jama.280.10.887
- Romanowski B, Aoki FY, Martel AY, et al. Efficacy and safety of famciclovir for treating mucocutaneous herpes simplex infection in HIV-infected individuals. AIDS. 2000;14(9):1211–1217.
- World Health Organization (WHO). WHO Model List of Essential Medicines – 23rd List (2023). Geneva: WHO; 2023.
Editorial Team
This article was written and medically reviewed by the iMedic Medical Editorial Team, comprising licensed specialist physicians in clinical pharmacology, infectious disease, and dermatology. Our editorial process follows international best practices for medical content creation:
All medical claims are supported by peer-reviewed literature, international guidelines (EMA, FDA, WHO, BNF, NICE), and systematic reviews. Evidence level: 1A.
Content is reviewed by board-certified physicians following the GRADE evidence framework. All sources are independently verified for accuracy and clinical relevance.
iMedic receives no pharmaceutical funding or advertising revenue. All content is produced independently without commercial influence or conflict of interest.
Articles are reviewed and updated at least annually to reflect new evidence, guideline changes, and regulatory updates. Last review: January 31, 2026.